Celltrion Accelerates Keytruda Biosimilar Trial, Eyes Faster Market Entry

Celltrion has made a big move to speed up its Keytruda biosimilar, CT-P51, for the U.S. market, cutting the number of patients in its main study from 600 to just 220. This quick change in their plan helps them get the drug ready faster, showing they are serious about being one of the first to offer a cheaper version of the world's top-selling cancer medicine. This is a bold step in the fight to make expensive cancer treatments more affordable. Keytruda, made by Merck & Co., is a special kind of medicine called immunotherapy that helps your body fight cancer. It made huge sales last year, but its main patent in the U.S. is ending around 2029. Many companies, like Samsung Bioepis, are rushing to create similar versions, called biosimilar, hoping to bring down costs and help more patients. Celltrion move suggests they have strong early results or are using new, faster rules from health authorities. Now, everyone will be watching to see how quickly Celltrion can finish this smaller study and get approval from the FDA, which is the main health body in the U.S. If CT-P51 gets approved quickly, it could be one of the first Keytruda biosimilar to hit the market, meaning more options and potentially lower prices for cancer patients. This race isn't just about medicine; it's about changing how cancer care is paid for and accessed globally.